Anatomic and molecular pathology of intrahepatic cholangiocarcinoma.

Intrahepatic cholangiocarcinoma (ICC) is the second most common malignant tumor of the liver, and ICC is reportedly increasing recently. ICC is usually adenocarcinoma with variable desmoplastic reaction, although there are several special or unusual histological features. ICC may arise at the large intrahepatic bile duct near the hepatic hilus and also from the bile ductules at the border of the hepatic parenchyma. On the anatomical level, the pathology of ICC differs depending on the region from which the ICC arises. At the large intrahepatic bile duct, ICC presents papillary growth and periductal infiltration. Some cases show extensive papillary growth and intraluminal spread with marked gastroenteric metaplasia. Mucus core protein 1 is expressed in aggressive ICC. ICC arising from ductules shares phenotypes of hepatocellular carcinoma. ICC in chronic biliary diseases, particularly arising in hepatolithiasis, presents precancerous lesions that include biliary epithelial dysplasia, as well as in-situ carcinoma. Chronic advanced hepatitis C is one of the background diseases of ICC. Chronic inflammation, with the upregulation of cyclooxygenase-2 and growth factors, and the formation of reactive oxygen species are one of the causative factors in the DNA damage of biliary epithelial cells. K- ras mutation and aberrant expression of p53 are found in one-third of ICCs. The latter may be due to mdm-2 upregulation. Hepatocyte growth factor/met and interleukin 6 (IL6)/IL6 receptor are involved in cell proliferation/mitoinhibition and apoptosis in ICC. Fibrous stroma formation and invasion involve the proliferation of Alpha-smooth muscle antigen-positive stromal cells, and cell-to-cell and cell-to-matrix interactions involving E-cadherin/catenin and CD44 and matrix proteinases may be involved in the invasion of ICC. Evasion of immune surveillance involving the Fas/FasL system is important in the malignant progression of ICC. Further molecular and genetic studies are mandatory to evaluate the pathogenesis and progression of ICC.

[1]  T. Roskams,et al.  Heparan sulphate proteoglycan expression in human primary liver tumours , 1998, The Journal of pathology.

[2]  R. Badolato,et al.  Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. , 1999, The American journal of pathology.

[3]  Y. Jan,et al.  Clinical studies of mucin-producing cholangiocellular carcinoma: a study of 22 histopathology-proven cases. , 1998, Annals of surgery.

[4]  Y. Okada,et al.  Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors , 1996, Hepatology.

[5]  H. Herbst,et al.  Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. , 1999, Journal of hepatology.

[6]  C. Ker,et al.  Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts , 2000, Hepatology.

[7]  T. Tsuji,et al.  Transforming Growth Factor-β1 Stimulates or Inhibits Cell Growth via Down- or Up-Regulation of p21/Waf1 , 1998 .

[8]  Y. Kim,et al.  Expression of apomucins in the intrahepatic biliary tree in hepatolithiasis differs from that in normal liver and extrahepatic biliary obstruction , 1998, Hepatology.

[9]  Yong Il Kim,et al.  Intraductal variant of peripheral cholangiocarcinoma of the liver with Clonorchis sinensis infection , 1989, Cancer.

[10]  I. Sugano,et al.  Intrahepatic cholangiocarcinoma with sarcomatous change. Clinicopathologic and immunohistochemical evaluation of seven cases , 1993, Cancer.

[11]  Y. Jan,et al.  Intraductal papillary neoplasia of the liver associated with hepatolithiasis , 2001, Hepatology.

[12]  K. Sugimachi,et al.  Expression and Antitumor Effects of TRAIL in Human Cholangiocarcinoma , 2000, Hepatology.

[13]  K. Takasaki,et al.  Minute nodular intrahepatic cholangiocarcinoma , 1998, Cancer.

[14]  H. Moses,et al.  TGF‐β regulation of epithelial cell proliferation , 1992, Molecular reproduction and development.

[15]  Y. Nakanuma,et al.  Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells: in situ and culture study. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[16]  R. Sampliner,et al.  Reduced bile acid-induced apoptosis in "normal" colorectal mucosa: a potential biological marker for cancer risk. , 1996, Cancer research.

[17]  Harada,et al.  Absence of Epstein–Barr virus (EBV) in intrahepatic cholangiocarcinoma confirmed by lack of EBV‐coded nuclear RNA and latent membrane protein‐1 , 2000, Histopathology.

[18]  Y. Nakanuma,et al.  Endocrine cells in the intrahepatic biliary tree in normal livers and hepatolithiasis. , 1989, Archives of pathology & laboratory medicine.

[19]  W. H. Kim,et al.  Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[20]  G. Gores,et al.  Inhibition of interleukin 6–mediated mitogen‐activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line , 1999, Hepatology.

[21]  M. Fiorentino,et al.  Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. , 1996, Gastroenterology.

[22]  A. Kopp-Schneider,et al.  Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma , 2001, Gut.

[23]  T. Miyazaki,et al.  Point mutation of K-ras gene codon 12 in biliary tract tumors. , 1994, Gastroenterology.

[24]  R. Colombari,et al.  Biliary Tumors of the Liver , 1995, Seminars in liver disease.

[25]  Y. Ishikawa,et al.  Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast. , 1999, Radiation research.

[26]  R. Iozzo,et al.  The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. , 1994, The Biochemical journal.

[27]  M. Tsuneyoshi,et al.  Intraductal papillary mucinous neoplasms of the pancreas associated with so-called "mucinous ductal ectasia". Histochemical and immunohistochemical analysis of 29 cases. , 1995, The American journal of surgical pathology.

[28]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[29]  K. Sugimachi,et al.  The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. , 2001, Journal of hepatology.

[30]  J. Lechago,et al.  Bile duct carcinoma associated with multiple von Meyenburg complexes in the liver. , 1986, Human Pathology.

[31]  T. Terada,et al.  Cell kinetic analyses and expression of carcinoembryonic antigen, carbohydrate antigen 19-9 and DU-PAN-2 in hyperplastic, pre-neoplastic and neoplastic lesions of intrahepatic bile ducts in livers with hepatoliths , 2005, Virchows Archiv A.

[32]  M. Miyazaki,et al.  Allelic loss in human intrahepatic cholangiocarcinoma: Correlation between chromosome 8p22 and tumor progression , 2000, International journal of cancer.

[33]  S. Hirohashi,et al.  Cholangiocarcinomas in japanese and thai patients: Difference in etiology and incidence of point mutation of the c‐KI‐ras proto‐oncogene , 1992, Molecular carcinogenesis.

[34]  M. Fiorentino,et al.  Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  J. Hirabayashi,et al.  Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. , 2001, Human pathology.

[36]  K. Imai,et al.  Effect of MUC1 Mucin, an Anti‐adhesion Molecule, on Tumor Cell Growth , 1996, Japanese journal of cancer research : Gann.

[37]  T. Terada,et al.  Pathologic features of hepatolithiasis in Japan. , 1988, Human pathology.

[38]  Y. Nakanuma,et al.  Frequent expression of mucin core protein MUC1 in non-neoplastic gallbladder mucosa from patients with pancreaticobiliary maljunction. , 1999, Liver.

[39]  L. Pilarski,et al.  The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. , 1996, Cancer research.

[40]  W. Kim,et al.  Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. , 2002, Human pathology.

[41]  G. Michalopoulos,et al.  Interleukin‐6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type i ductular reaction in mice: Interactions between the periductal inflammatory and stromal cells and the biliary epithelium , 1998, Hepatology.

[42]  B. Davidson,et al.  The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. , 2001, Journal of clinical pathology.

[43]  K. Tsuneyama,et al.  Up‐regulation of Fas ligand at early stages and down‐regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance , 2000, Hepatology.

[44]  N. Kinukawa,et al.  The role of p27kip1 protein expression on the biological behavior of intrahepatic cholangiocarcinoma , 2001, Hepatology.

[45]  M. Omata,et al.  High incidence of ras gene mutation in intrahepatic cholangiocarcinoma , 2010, Cancer.

[46]  J. Shelhamer,et al.  Involvement of 85‐kd cytosolic phospholipase A2 and cyclooxygenase‐2 in the proliferation of human cholangiocarcinoma cells , 2002, Hepatology.

[47]  K. Tsuneyama,et al.  Oncocytic Biliary Cystadenocarcinoma Is a Form of Intraductal Oncocytic Papillary Neoplasm of the Liver , 2001, Modern Pathology.

[48]  H. Miyazato,et al.  Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. , 2002, Hepato-gastroenterology.

[49]  T. Terada,et al.  Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. , 1998, Human pathology.

[50]  F. Que,et al.  Dysregulation of Apoptosis in the Cholangiopathies and Cholangiocarcinoma , 1998, Seminars in liver disease.

[51]  J. Lunz,et al.  Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin a: Comparison of a cholangiocarcinoma cell line with primary cultures of non‐neoplastic biliary epithelial cells , 2000, Hepatology.

[52]  Keizo Sugimachi,et al.  Enhanced expression of thrombospondin‐1 and hypovascularity in human cholangiocarcinoma , 1998, Hepatology.

[53]  Y. Kawarada,et al.  Analysis of microsatellite instability, TGF-beta type II receptor gene mutations and hMSH2 and hMLH1 allele losses in pancreaticobiliary maljunction-associated biliary tract tumors. , 1999, Anticancer research.

[54]  M. Monden,et al.  Differential expression of cyclooxygenase‐2 (COX‐2) in human bile duct epithelial cells and bile duct neoplasm , 2001, Hepatology.

[55]  G. Stamp,et al.  MUC1 expressed in PanC1 cells decreases adhesion to type 1 collagen but increases contraction in collagen lattices. , 1996, The American journal of pathology.

[56]  Y. Hinoda,et al.  Increased invasiveness of MUCI1 cDNA‐transfected human gastric cancer MKN74 cells , 1998, International journal of cancer.

[57]  K. Batts,et al.  Papillary bile duct dysplasia in primary sclerosing cholangitis. , 1992, Gastroenterology.

[58]  Y. Kim,et al.  Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: An immunohistochemical study , 1996, Hepatology.

[59]  Y. Nakanuma,et al.  Relationship between interleukin‐6 and proliferation and differentiation in cholangiocarcinoma , 1998, Histopathology.

[60]  P. Gaulard,et al.  Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. , 1994, The American journal of pathology.

[61]  Y. Jan,et al.  Increasing expression of gastrointestinal phenotypes and p53 along with histologic progression of intraductal papillary neoplasia of the liver. , 2002, Human pathology.

[62]  S. Horie,et al.  c‐erbB‐2 protein is expressed in hepatolithiasis and cholangiocarcinoma , 1998, Histopathology.

[63]  A. Yayon,et al.  Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis , 1994, Cell.

[64]  R. Hruban,et al.  Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. , 1998, Cancer research.

[65]  K. Endo,et al.  Increased midkine expression in intrahepatic cholangiocarcinoma: immunohistochemical and in situ hybridization analyses. , 2000, Liver.

[66]  T. Terada,et al.  Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. , 1995, Human pathology.

[67]  A. Raz,et al.  Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. , 1999, Cancer research.

[68]  J. Boyer,et al.  Biliary catabolism of glutathione and differential reabsorption of its amino acid constituents. , 1988, The American journal of physiology.

[69]  J. Wyatt,et al.  p53 but not bcl‐2 is expressed by most cholangiocarcinomas: a study of 28 cases , 1999, Histopathology.

[70]  G. Gores,et al.  Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. , 2001, Gastroenterology.

[71]  J. Weidner,et al.  Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. , 1996, Gastroenterology.

[72]  P. Steiner,et al.  Cholangiolocellular carcinoma of the liver , 1959, Cancer.

[73]  T. Terada,et al.  Expression of e‐cadherin, α‐catenin, β‐catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: An immunohistochemical study , 1998 .

[74]  W. Kim,et al.  Allelotype Analysis of Intrahepatic Cholangiocarcinoma , 2000, Modern Pathology.

[75]  Y. Nakanuma,et al.  Distribution of apoptotic cells and expression of apoptosis‐related proteins along the intrahepatic biliary tree in normal and non‐biliary diseased liver , 2000, Histopathology.

[76]  S. Horie,et al.  Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features , 2000, Virchows Archiv.

[77]  Y. Nakanuma,et al.  Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver , 2000, Histopathology.

[78]  Y. Nakanuma,et al.  Pathological and immunohistochemical findings in a case of mucinous cholangiocarcinoma , 1995, Pathology international.

[79]  Y. Kondō,et al.  A clinicopathologic study of intrahepatic cholangiocarcinoma containing a component of squamous cell carcinoma , 1990, Cancer.

[80]  Y. Jan,et al.  Human REG I gene is up‐regulated in intrahepatic cholangiocarcinoma and its precursor lesions , 2001, Hepatology.

[81]  Y. Nakanuma,et al.  Biliary papillary neoplasm of the liver. , 2002, Histology and histopathology.

[82]  G. Michalopoulos,et al.  Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: Interleukin‐6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro , 1994, Hepatology.

[83]  T. Terada,et al.  Histological features and interphase nucleolar organizer regions in hyperplastic, dysplastic and neoplastic epithelium of intrahepatic bile ducts in hepatolithiasis , 1992, Histopathology.

[84]  C. Bouvier,et al.  E‐cadherin quantititive immunocytochemical assays in breast carcinomas , 1997, The Journal of pathology.

[85]  T. Kuo,et al.  Intrahepatic Cholangiocarcinoma with Lymphoepithelioma-Like Component , 2001, Modern Pathology.

[86]  T. Terada,et al.  Are hepatolithiasis and cholangiocarcinoma aetiologically related? , 1985, Virchows Archiv A.

[87]  M. Monden,et al.  bcl-2 Expression in Cholangiocellular Carcinoma Is Inversely Correlated with Biologically Aggressive Phenotypes , 2000, Oncology.

[88]  M. Tsuneyoshi,et al.  The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[89]  K. Tsuneyama,et al.  Enhanced expression of basement‐membrane‐type heparan sulfate proteoglycan in tumor fibro‐myxoid stroma of intrahepatic cholangiocarcinoma , 2001, Pathology international.

[90]  Y. Nakanuma,et al.  Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply , 1997, Microscopy research and technique.

[91]  S. Satoh,et al.  Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. , 2001, Journal of hepatology.

[92]  G. Huang,et al.  Clonal Epstein-Barr virus associated cholangiocarcinoma with lymphoepithelioma-like component. , 1996, Human pathology.

[93]  M. Zeng,et al.  Fas-induced caspase denitrosylation. , 1999, Science.

[94]  S. Finkelstein,et al.  Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study , 2001, Journal of Cancer Research and Clinical Oncology.

[95]  Toshikazu Nakamura,et al.  Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated “intestinal‐type” biliary cancer chemically induced in rat liver , 2000, Hepatology.

[96]  N. Bertin,et al.  Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. , 1997, Cancer research.

[97]  W. Su,et al.  Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. , 1995, Anticancer research.

[98]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[99]  A. Demetris,et al.  Acute obstructive cholangiopathy in interleukin-6 deficient mice: compensation by leukemia inhibitory factor (LIF) suggests importance of gp-130 signaling in the ductular reaction. , 2000, Liver.

[100]  F. Sommerer,et al.  Genetic and epigenetic alterations of the INK4a–ARF pathway in cholangiocarcinoma , 2002, The Journal of pathology.

[101]  P. Sithithaworn,et al.  Liver flukes and liver cancer , 1999 .

[102]  J. Haratake,et al.  Giant cell tumor‐like cholangiocarcinoma associated with systemic cholelithiasis , 1992, Cancer.

[103]  G. Gores,et al.  Bcl‐2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line , 1997, Hepatology.

[104]  K. Sugimachi,et al.  Altered Expression of β-Catenin without Genetic Mutation in Intrahepatic Cholangiocarcinoma , 2001, Modern Pathology.

[105]  Harada,et al.  Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma , 1999, Histopathology.

[106]  H. Ohtani,et al.  Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. , 2008, Liver.

[107]  T. Terada,et al.  Pathological observations of intrahepatic peribiliary glands in 1,000 consecutive autopsy livers. II. A possible source of cholangiocarcinoma , 1990, Hepatology.

[108]  C. Marshall,et al.  Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. , 1991, Cancer research.

[109]  Y. Nakanuma,et al.  In situ nucleic acid detection of human telomerase in intrahepatic cholangiocarcinoma and its preneoplastic lesion , 1999, Hepatology.

[110]  Z. Rudzki,et al.  CD44 and the adhesion of neoplastic cells. , 1997, Molecular pathology : MP.

[111]  K. Tsuneyama,et al.  Expression of MUC1 and MUC2 and carbohydrate antigen Tn change during malignant transformation of biliary papillomatosis , 2001, Histopathology.

[112]  M. Hollingsworth,et al.  MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: its close relationship with prognosis of the patients. , 1997, Human pathology.

[113]  T. Terada,et al.  Glandular elements around the intrahepatic bile ducts in man; their morphology and distribution in normal livers. , 2008, Liver.

[114]  T. Irimura,et al.  Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: Its relationship with a new morphological classification of cholangiocarcinoma , 1999, Hepatology.

[115]  M. Kojiro,et al.  Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma. A study of 57 autopsy‐proven cases , 1977, Cancer.

[116]  M. Pierotti,et al.  TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas. , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[117]  Y. Konishi,et al.  Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. , 1995, Gastroenterology.

[118]  M. Tsuneyoshi,et al.  The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of 'scirrhous-type' and 'nonscirrhous-type' growth. , 1999, The American journal of surgical pathology.

[119]  Masakazu Yamamoto,et al.  Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular‐cholangiocarcinoma) in Japan , 1993, Cancer.

[120]  M. Pignatelli,et al.  Adhesion molecules: novel molecular tools in tumor pathology. , 1994, Human pathology.

[121]  Y. Kim,et al.  Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles. , 1998, American journal of clinical pathology.

[122]  Y. Nakanuma,et al.  Intrahepatic cholangiocarcinoma arising in congenital hepatic fibrosis: report of an autopsy case. , 1998, Journal of hepatology.

[123]  I. Lax,et al.  Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? , 1995, Cell.

[124]  Makimoto Kiyoko,et al.  Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. , 1996 .